INT193493

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2006
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.77
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

tor (Mus musculus)
Pain Link Frequency Relevance Heat
Potency 1 98.48 Very High Very High Very High
corticosteroid 42 96.78 Very High Very High Very High
withdrawal 17 87.28 High High
antagonist 14 5.00 Very Low Very Low Very Low
imagery 5 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
addiction 2 5.00 Very Low Very Low Very Low
tolerance 2 5.00 Very Low Very Low Very Low
Clonidine 1 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Malignant Neoplastic Disease 15 97.28 Very High Very High Very High
Graft Vs Host Disease 1 96.28 Very High Very High Very High
Renal Failure 10 95.08 Very High Very High Very High
Sarcoma 2 94.32 High High
Disease 46 81.16 Quite High
Neurodegenerative Disease 12 73.52 Quite High
Metastasis 1 72.04 Quite High
Cancer 27 70.16 Quite High
Delayed Graft Function 23 69.96 Quite High
Targeted Disruption 15 65.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These and other studies indicate that TOR inhibitors have an equivalent immunosuppressive potency but a reduced risk of malignancy.
Negative_regulation (inhibitors) of TOR associated with malignant neoplastic disease and potency
1) Confidence 0.25 Published 2006 Journal BMC Nephrol Section Body Doc Link PMC1501004 Disease Relevance 1.07 Pain Relevance 0.05
An understanding of the function of TOR function as a negative regulator of autophagy allowed researchers to exploit rapamycin, an inhibitor of TOR, as a means to induce autophagy.
Negative_regulation (inhibitor) of TOR
2) Confidence 0.12 Published 2008 Journal Biochim Biophys Acta Section Body Doc Link PMC2597715 Disease Relevance 0.54 Pain Relevance 0
The current role for basiliximab in the evolution of the renal transplant immunosuppressive protocol, however, appears to be as induction when corticosteroids are to be withdrawn rapidly following transplantation or when the calcineurin inhibitor is to be administered at reduced doses or avoided in association with a TOR inhibitor in low- and standard-risk patients.
Negative_regulation (inhibitor) of TOR associated with corticosteroid and renal failure
3) Confidence 0.04 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721359 Disease Relevance 0.17 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox